Details
Stereochemistry | ACHIRAL |
Molecular Formula | CO3.2Na |
Molecular Weight | 105.9884 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[O-]C([O-])=O
InChI
InChIKey=CDBYLPFSWZWCQE-UHFFFAOYSA-L
InChI=1S/CH2O3.2Na/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CO3 |
Molecular Weight | 60.0089 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Potash (Dihydroxyaluminum Sodium Carbonate), a component of
Kompensan-S Forte in Germany, is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Kompensan-S Forte is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL261 Sources: https://www.drugbank.ca/drugs/DB09460 |
|||
Target ID: CHEMBL205 Sources: https://www.drugbank.ca/drugs/DB09460 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Kompensan Approved UseGastrointestinal disorders: Dyspepsia, Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Hyperphosphatemia |
Sample Use Guides
Usual Adult Dose for Dyspepsia: 500 to 600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Duodenal Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Erosive Esophagitis: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastric Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastroesophageal Reflux Disease: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Zollinger-Ellison Syndrome: 500 to 3600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Hyperphosphatemia: 500 to 1000 mg orally 4 times a day, with meals and at bedtime. The dosage should be titrated to the serum phosphate level.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 00:03:20 UTC 2023
by
admin
on
Thu Jul 06 00:03:20 UTC 2023
|
Record UNII |
45P3261C7T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-500(I)
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
||
|
DSLD |
2044 (Number of products:3)
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
||
|
CFR |
21 CFR 184.1742
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
||
|
EPA PESTICIDE CODE |
73506
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
||
|
NCI_THESAURUS |
C29730
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
||
|
WHO-ATC |
A02AB04
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
||
|
JECFA EVALUATION |
INS-500(I)
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
45P3261C7T
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
497-19-8
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
36685
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | RxNorm | ||
|
10340
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
1613757
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
45P3261C7T
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
5018
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
207-838-8
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
C005686
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
100000078105
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
DTXSID1029621
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
M10001
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | Merck Index | ||
|
C47721
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
INS-500(I)
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
5132
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
CHEMBL186314
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
SUB12580MIG
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
156204
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
SODIUM CARBONATE
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
29377
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
SUB15279MIG
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY | |||
|
DB09460
Created by
admin on Thu Jul 06 00:03:20 UTC 2023 , Edited by admin on Thu Jul 06 00:03:20 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |